In Silico Drug Designing on HIV

Abstract

With millions of cases of infection worldwide, the human immunodeficiency virus (HIV) continues to be a serious global health concern. While combination anti-retroviral therapy has significantly improved outcomes, drug resistance, toxicity, and the need for lifelong treatment necessitate ongoing efforts to develop new anti-HIV agents with novel mechanisms of action. In silico drug design methods leverage increasing computing power and knowledge of HIV biology to accelerate the identification of promising drug candidates. The primary computational methods for HIV drug discovery are outlined in this research, including machine learning, pharmacophore modelling, molecular docking, quantitative structure-activity relationship (QSAR) analysis, and molecular dynamics simulations.

 We discuss successful applications of these techniques to design inhibitors of critical HIV targets like reverse transcriptase, protease, and integrase, as well as entry and maturation inhibitors. Multi-target drug design strategies are highlighted. The challenges and limitations of current methods are examined. Finally, emerging frontiers in anti-HIV drug development are explored, such as targeting host factors, leveraging cryo-EM data, and employing artificial intelligence. The discovery and creation of in silico drugs will remain crucial to broaden the anti-HIV armaments and advance their battle against the virus closer to victory.